|
AU2007214351A1
|
|
Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
|
|
CA2600359A1
|
|
Nucleosides with non-natural bases as anti-viral agents
|
|
BRPI0512360A
|
|
5-aza-7-deazapurine derivatives for the treatment of flaviviridae
|
|
IL165757D0
|
|
2'-c-methyl-3'o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
CN101418028A
|
|
Synthesis of beta-l-2-deoxy nucleosides
|
|
NZ544634A
|
|
Synthesis of beta-l-2-deoxy nucleosides
|
|
WO2005020884A2
|
|
Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
|
|
WO2004096149A2
|
|
Industrially scalable nucleoside synthesis
|
|
EP1620407A2
|
|
Oxo-pyrimidine compounds
|
|
AU2004201286A1
|
|
Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
|
|
AU2003300434A1
|
|
Process for the production of 3'-nucleoside prodrugs
|
|
MXPA05006230A
|
|
Process for the production of 2'-branched nucleosides.
|
|
CN1744903A
|
|
Process for the production of 2'-branched nucleosides
|
|
CN1777363A
|
|
Ss-l-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
|
|
NZ537662A
|
|
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
RU2437892C2
|
|
Modified 2- and 3-nucleosides and use thereof to produce medicinal agent, having hepatitis c inhibiting activity
|
|
RS114104A
|
|
2' and 3'-nucleoside prodrugs for treating flaviviridae infections
|
|
CN1761677A
|
|
Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
|
|
PL374781A1
|
|
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
WO03026675A1
|
|
Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
|
